Us Bancorp \De\ Cellectar Biosciences, Inc. Transaction History

Us Bancorp \De\

  • $77.3 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 04, 2020
SELL
$10.6 - $24.1 $10 - $24
-1 Reduced 0.03%
2,858 $6,000
Q3 2018

Nov 01, 2018
BUY
$21.9 - $79.0 $62,612 - $225,861
2,859 New
2,859 $9,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.59M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email